ADRIAN APOSTOL, LAZAR CHISAVU, NICOLAE ALBULESCU, DANA STOIAN, ADALBERT SCHILLER RAS INHIBITION IN HAEMODYALISIS PATIENTS. IMPACT ON MORTALITY Patients with chronic kidney disease (CKD) represent a special category of risk. As part of the renal and cardiovascular continuum from risk factors to end stage diseases, they develop clinical syndromes with potentially severe prognosis. Patients on dialysis have severe cardiac risk, have a peculiar hyperlipemic profile with intense atherogenic effect, phosphocalcic metabolic alterations and thus a higher rate of development of atheroma and degenerative valve diseases. They have higher cardiovascular mortality and morbidity being potential candidates for aggressive reduction of risk factors. Dialysate patients are exposed to higher risk of ischemic and arrhythmic events. Echocardiographic assessment of these patients is extremely important in risk stratification and treatment strategy in order to improve prognosis. Drugs proved to improve cardiac remodeling, reduce hypertrophy and LV mass and enhance ejection fraction, improved prognosis.